Zhongchao Inc. (NASDAQ: (ZCMD) stock plunged by 3.54% in the pre-market trading session. Zhongchao Inc. is a platform-based internet technology business founded in 2012 with headquarters in Shanghai and Beijing, China. The Company also runs a platform that provides patient management solutions through its subsidiaries.
ZCMD stock’ Current Update
Zhongchao Inc. claimed that its self-developed patient management system has increased the duration of therapy for liver cancer patients by 40.4 percent. It resulted in increased drug efficiency, successful treatment, and also extended patient survival times.
Zhongchao provided people with a cohesive treatment process management by applying its self-developed patient management system. It assists patients by providing education, psychological counseling, reminders about drug consumption, answers to treatment-related inquiries, and patient monitoring to make sure that they follow instructions as given. According to a study published in the BMJ, good adherence was related to decreased mortality, with death chances reduced by 44 percent in individuals who adhered well.
Furthermore,
As per the Global Cancer Observatory, over 400,000 new instances of liver cancer will be diagnosed in China year 2020. Surgical resection, interventional therapy, radiation, and liver transplantation are the most common treatments for liver cancer. While each treatment approach has its own set of limitations, combining them with systemic therapies such as targeted medications might improve the treatment’s effectiveness.
During systemic therapy, one or more adverse responses frequently impair patients’ quality of life and impede their mental health, raising treatment difficulties and having a detrimental effect on patients’ survival terms. As a result, during therapy, Zhongchao employs its patient management system to continuously monitor and control adverse responses, as well as coordinate follow-up visits to help patients better their physical and mental health. The company will continue to invest in its patient management system, with the goal of making it more accessible to all cancer patients.
